The single-arm phase 2 RTOG 0420 trial of chemo intensification following standard chemoradiation for glioblastoma demonstrates a median survival of 17 months with the addition of irinotecan to one year of adjuvant temozolomide. This is right in line with the adjuvant temozolomide-alone (aka losing) arm in EF-14. | Lieberman, Int J Radiat Oncol Biol Phys 2018


Popular Posts